Eli Lilly and Company

Stratagene California

Other

Stratagene

Peter Edward Vaillancourt

Jeffry Dean Watkins

Julian Davies

David Matthew Marquis

Ying Tang

Jirong Lu

Ling Liu

Joseph A Sorge

Craig Duane Dickinson

Victor H Obungu

Sheng-Bin Peng

Ronald W Davis

Bryan Edward Jones

Donmienne Doen Mun Leung

Lihua Huang

Scott William Rowlinson

Mark Andrew Wortinger

Cindy Takeuchi Dickerson

Wei Zeng

Jianghuai Xu

Vivian Qingqing Zhang

Irene Jennifer Denning

Gregory Beuerlein

The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.

VEGFA/Ang2 Compounds

The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.

Anti-c-met antibodies

Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.

c-Met antibodies

TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

Methods of using TGF-&#x3b2; 1 binding compositions

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

Anti-CXCR4 antibodies

Antibodies to TGF-beta 1

The invention relates to proteins or polypeptides that comprise intramolecular dimers of fluorescent protein monomers. More specifically, the invention relates to recombinant polypeptides comprising a monomer of a fluorescent polypeptide, a linker peptide, and a second monomer of that fluorescent polypeptide, where the monomers form an intramolecular dimer. The invention also relates to nucleic acids encoding Intramolecular Dimer Fluorescent Proteins (IDFPs) and vectors comprising such nucleic acids. The invention further relates to methods of making IDFPs and methods of using them. IDFPs are, useful in any application suited for fluorescent proteins and are particularly useful in applications in which more than one fluorescent protein sharing complementary dimerization interfaces is present in the same mixture or is expressed in the same cell, because IDFPs do not form heterodimers.

Dimeric flourescent polypeptides

The present invention provides a polynucleotide encoding a green fluorescent protein fromcomprising a humanized sequence which permits enhanced expression of the encoded polypeptide in mammalian cells.

Humanized polynucleotide sequence encoding Renilla mulleri green fluorescent protein

A method of titering adeno-associated virus particles in a sample, said method comprising the steps of contacting target cells with a DNA synthesis inhibitor and an agent that increases the activity of the CMV immediate early promoter; contacting target cells treated as in step (a) with a sample containing adeno-associated virus particles; and determining the number of target cells infected by said adeno-associated virus particles in said sample, wherein said number of target cells infected is directly proportional to the titer of said particles in said sample, thereby determining the titer if said adeno-associated virus particles.

Method and kits for titering adeno-associated virus vectors

The present invention provides a polynucleotide encoding a green fluorescent protein from comprising a humanized sequence which permits enhanced expression of the encoded polypeptide in mammalian cells.

Growing community of inventors

Del Mar, CA, United States of America

Peter Edward Vaillancourt